海外演者紹介
10：30〜11：30
●シンポジウム３（共催：株式会社パイオラックス）
「肝動注療法 海外の現況と今後の展開 Current status of arterial-port outside Japan」
座長：曽根 美雪（国立がん研究センター放射線診断科・IVRセンター）
田中 利洋（奈良県立医科大学 放射線診断・IVR学教室）
S3-1 『Current status of HAIC in Japan』
菅原 俊祐 （日本）
S3-2 『Our clinical practice and research topics on HAIC for HCC』
Ho Jong Chun （韓国）
S3-3 『Our techniques and results of HAIC for HCC』
Huei Lung, Liang （台湾）
S3-4 『HAIC using FOLFOX for HCC』
Ming Zhao （中国）
S3-5 『Arterial-Port in my Clinical Practice for mCRC』
Frederic Deschamps （フランス）
パネルディスカッション Drs. 菅原, Chun, Liang, Zhao
Dr. Ho Jong Chun（韓国）
|
Professor, Dept of Radiology, Seoul St. Mary’s Hospital 韓国で肝動注の第一人者。2007年に大阪大学放射線科に留学経験あり。 |
肝動注関連 英語論文
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy.
Sung PS, Chun HJ, et al.Front Oncol. 2020 Nov 19;10:600233.
Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma.
Sung PS, Chun HJ, et al. Anticancer Res. 2019 Jul;39(7):3909-3916.
Dual-Port versus Mono-Port Implantation for Intra-Arterial Chemoinfusion Therapy for Treatment of Hepatocellular Carcinoma in Patients with Anatomic Hepatic Artery Variation.
Kim SH, Chun HJ, et al .J Vasc Interv Radiol. 2019 Jan;30(1):23-30.
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
Song MJ, Chun HJ, et al, Eun JR.Cancer Chemother Pharmacol. 2015 Apr;75(4):739-46.
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Song DS, Chun HJ, et al. World J Gastroenterol. 2013 Aug 7;19(29):4679-88
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Woo HY, Chun HJ, et al. Korean Liver Cancer Study Group.Cancer Chemother Pharmacol. 2010 Jan;65(2):373-82.
Dr. Huei-Lung Liang（台湾）
|
|
Head, Dept of Radiology, Kaohsiung Veterans General Hospital 台湾で古くから肝動注を行っている。台湾IVR学会の代表であり、本年アジアオセアニアIVR学会(APSCVIR 2021)の会長を務められた。 |
肝動注関連 英語論文
Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma.
Tsai WL, Liang HL, et al. Medicine (Baltimore). 2020 Aug 7;99(32):e21489.
Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment.
Hsiao JH, Liang HL, et al. Int J Surg. 2017 Sep;45:35-41.
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
Tsai WL, Liang HL, et al. PLoS One. 2014 May 13;9(5):e92784.
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route.
Liang HL, et al. Acta Radiol. 2007 Sep;48(7):734-40.
Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
Lin CP, Liang HL, et al. J Chin Med Assoc. 2004 Dec;67(12):602-10.
Dr. Ming Zhao（中国）
|
Professor, Associate Director of Minimally Invasive Interventional department Sun Yat-sen University Cancer Center 中国でHCCに対するオキザリプラチン肝動注を行っている。無作為比較試験の結果がJAMAオンコロジーに掲載。 |
肝動注関連 英語論文
Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
Li S, Lyu N, Zhao M, et al. J Vasc Interv Radiol. 2021 Jun 22:S1051-0443(21)01160-X. doi: 10.1016/j.jvir.2021.06.008. Online ahead of print.
Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy.
Liu S, Zhao M, et al. Front Oncol. 2021 Feb 1;10:582504.
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
He M, Zhao M, et al. JAMA Oncol. 2019 Jul 1;5(7):953-960.
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
Lyu N, Zhao M, et al. J Vasc Interv Radiol. 2019 Mar;30(3):349-357.e2.
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N, Zhao M, et al. J Hepatol. 2018 Jul;69(1):60-69.
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Lyu N, Zhao M, et al. Gut. 2018 Feb;67(2):395-396.
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Li C, Zhao M, et al. Cancer Chemother Pharmacol. 2014 Nov;74(5):1079-87.
Dr Frédéric Deschamps（フランス）
|
Département de Radiologie Interventionnelle, Gustave Roussy フランスパリの郊外にあるIVRの有名な施設。荒井保明先生の友人であるde Baere先生がボスであり、リザーバー肝動注を伝授されたとのこと。愛知県がんセンターの稲葉吉隆先生、国立がん研究センター中央病院の菅原俊祐先生、岡山大学の生口俊浩先生が留学されていた。 |
肝動注関連 英語論文
Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model.
Deschamps F, et al. Drug Deliv Transl Res. 2021 Jan 11.
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D, Deschamps F, et al. BMC Cancer. 2018 Aug 6;18(1):787.
The role of image-guided therapy in the management of colorectal cancer metastatic disease.
de Baere T, Deschamps F, et al. Eur J Cancer. 2017 Apr;75:231-242.
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
de Baere T, Deschamps F, et al. Bull Cancer. 2017 May;104(5):402-406.
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D, Deschamps F, et al. Ann Surg. 2013 Jan;257(1):114-20.
Interventional revisions of malfunctions affecting surgically implanted port-catheters for hepatic artery infusion.
Farouil G, Deschamps F, et al. Surg Oncol. 2013 Mar;22(1):48-54.